Steven Cohen's LCTX Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 304,363 shares of Lineage Cell Therapeutics, Inc. (LCTX) worth $480,894, representing 0.00% of the portfolio. First purchased in 2023-Q1, this short-term holding has been held for 4 quarters.
Based on 13F filings, Steven Cohen has maintained this position in LCTX for several quarters, showing initial confidence in the investment. Largest addition occurred in Q4 2025, adding 159,408 shares. Largest reduction occurred in Q2 2023, reducing 13,786 shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's Lineage Cell Therapeutics (LCTX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Lineage Cell Therapeutics (LCTX) Trades by Steven Cohen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +144,955 | Add 90.93% | 304,363 | $1.58 |
| Q4 2025 | +159,408 | New Buy | 159,408 | $1.67 |
| Q2 2023 | -13,786 | Sold Out | 0 | $0.00 |
| Q1 2023 | +13,786 | New Buy | 13,786 | $1.50 |
Steven Cohen's Lineage Cell Therapeutics Investment FAQs
Steven Cohen first purchased Lineage Cell Therapeutics, Inc. (LCTX) in Q1 2023, acquiring 13,786 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held Lineage Cell Therapeutics, Inc. (LCTX) for 4 quarters since Q1 2023.
Steven Cohen's largest addition to Lineage Cell Therapeutics, Inc. (LCTX) was in Q4 2025, adding 159,408 shares worth $266,211.
According to the latest 13F filing for Q1 2026, Steven Cohen's firm, Point72 Asset Management, L.P., owns 304,363 shares of Lineage Cell Therapeutics, Inc. (LCTX), valued at approximately $480,894.
As of the Q1 2026 filing, Lineage Cell Therapeutics, Inc. (LCTX) represents approximately 0.00% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.
Steven Cohen's peak holding in Lineage Cell Therapeutics, Inc. (LCTX) was 304,363 shares, as reported at the end of Q1 2026.